T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy

Journal of Endocrinological Investigation

Volumn 26, Issue 10, 2003, Pages 979-984

  Mastorakos, G ^a,b   Doufas, A G ^a,b   Mantzos, E ^a,b   Mantzos, J ^a,b   Koutras, D A ^a,b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Evgenidion University Hospital   (Greece)

Author keywords

Antithyroid drug treatment (ATD); Graves' disease; Hyperthyroidism

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; LIOTHYRONINE; PLACEBO; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; AUTOANTIGEN; IODIDE PEROXIDASE; IRON BINDING PROTEIN; THYROTROPIN; TPO PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GOITER; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; STATISTICAL ANALYSIS; THYROID WEIGHT; THYROXINE BLOOD LEVEL; ADOLESCENT; BLOOD; HORMONE SUBSTITUTION; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SURVIVAL;

ADOLESCENT; ADULT; AGED; ANTITHYROID AGENTS; AUTOANTIGENS; CARBIMAZOLE; FEMALE; GRAVES DISEASE; HORMONE REPLACEMENT THERAPY; HUMANS; IODIDE PEROXIDASE; IRON-BINDING PROTEINS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL ANALYSIS; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE;

EID: 0346998322     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03348195     Document Type: Article

References (24)

1. Astwood E.B. Treatment of hyperthyroidism with thiourea and thiouracil. J.A.M.A. 1943, 122: 78-81.
2. Wartofsky L., Glinoer D., Solomon B, et al. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan and the United States. Thyroid 1991, 1: 129-135.
3. Hedley A.J., Young R.E., Jones S.J., Alexander W.D., Bewsher P.D., Scottish Automated Follow-Up Register Group. Antithyroid drugs in the treatment of hyperthyroidism of Graves' disease: Long-term follow-up of 434 patients. Clin. Endocrinol. (Oxf.) 1989, 31: 209-218.
4. Schleusener H., Schwander J., Fischer C., et al. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease. Acta Endocrinol. (Copenh.) 1989, 120: 689-701.
5. Törring O., Tallstedt L., Wallin G., et al. Graves' hyperthyroidism: Treatment with antithyroid drugs, surgery, or radioiodine - A prospective randomized study. J. Clin. Endocrinol. Metab. 1996, 81: 2986-2993.
6. Mastorakos G., Doufas A.G., Mantzos J., Koutras D.A. Long-term follow-up of 202 patients with Graves' disease treated medically. Thyroidology 1997, 9: 71-80.
7. Hashizume K., DeGroot L.J. Release of thyrotropin receptor from thyroid plasma membranes: Effect of hydrocortisone, propanolol, and adenosine 3′,5′-monophosphate. Endocrinology 1980, 106: 1463-1468.
8. Hashizume K., Ichikawa K., Sakurai K., et al. Administration of thyroxine in treated Graves' disease: Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N. Engl. J. Med. 1991, 324: 947-953.
9. Hashizume K., Ichikawa K., Nishii Y., et al. Effects of administration of thyroxine on the risk of postpartum recurrence of hyperthyroid Graves' disease. J. Clin. Endocrinol. Metab. 1992, 75: 6-10.
10. Doufas A.G., Mastorakos G., Mantzos J., Koutras D.A. Recurrence of Graves' disease is independent of thyroxine administration after medical therapy. Thyroid 1995, 5 (SUPPL. 1): S70.
11. McIver B., Rae P., Beckett G., Wilkinson E., Gold A., Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N. Engl. J. Med. 1996, 334: 220-224.
12. Pfeilschifter J., Ziegler R. Suppression of serum thyrotropin with thyroxine in patients with Graves' disease: Effects on recurrence of hyperthyroidism and thyroid volume. Eur. J. Endocrinol. 1997, 136: 81-86.
13. Rittmaster R.S., Abbot E.C., Douglas R., et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. J. Clin. Endocrinol. Metab. 1998, 83: 814-818.
14. Mantzos J.D., Yialouris P.P. A simple and reproducible method for the estimation of triiodothyronine uptake (thyroxine binding index) using a new adsorbent. Clin. Biochem. 1982, 15: 76-79.
15. Statistica Software for Windows. Copyright © 1984-1994 by StatSoft, Inc., Tulsa, Oklahoma.
16. Doufas A.G., Mastorakos G., Chatziioannou S., et al. The predominant form of non-toxic goiter in Greece is now autoimmune thyroiditis. Eur. J. Endocrinol. 1999, 140: 505-511.
17. Lucas A, Salinas I, Rius F, et al. Medical therapy of Graves disease: Does thyroxine prevent recurrence of hyperthyroidism? J. Clin. Endocrinol. Metab. 1997, 82: 2410-2413
18. Garcia-Mayor R.V., Paramo C., Luna Cano R., Perez Mendez L.F., Galofre J.C., Andrade A. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endocrinol. Invest. 1992, 15: 815-820.
19. Vitti P., Rago R., Chiovato L., et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997, 7: 369-375.
20. Feldt-Rasmussen U., Schleusener H., Carayon P. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease. J. Clin. Endocrinol. Metab. 1994, 78: 98-102.
21. Rink T., Holle L.H., Schroth H.J., Garth H. Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease. Nuklearmedizin 1998, 37: 90-94.
22. Keck F.S., Loos U. Peripheral autoregulation of thyromimetic activity in man. Horm. Metab. Res. 1988, 20: 110-114.
23. Glinoer D., De Nayer P., Bex M. Effects of I-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: A double-blind prospective randomized study. Eur. J. Endocrinol. 2001, 144: 475-483.
24. Bartalena L. Smoking and Graves' disease. J. Endocrinol. Invest. 2002, 25: 402.